Evidence map›Paper›PMID 40182774›Full record

ArticleFrontiers in cellular and infection microbiology2025

Bacteriocin KvarM versus conventional antibiotics: comparative effectiveness in treating

Indre Karaliute, Deimante Tilinde, Rima Ramonaite, Rokas Lukosevicius, Darja Nikitina, Jurga Bernatoniene, Irma Kuliaviene, Irena Valantiene, Dalius Petrauskas, Vilma Zigmantaite and 6 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Indre KaraliuteInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Deimante TilindeInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Rima RamonaiteInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Rokas LukoseviciusInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Darja NikitinaInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Jurga BernatonieneDepartment of Drug Technology and Social Pharmacy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Irma KuliavieneDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Irena ValantieneDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Dalius PetrauskasDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Vilma ZigmantaiteBiological Research Center, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Audrius MisiunasNomads UAB, Vilnius, Lithuania.
Erna DenkovskieneNomads UAB, Vilnius, Lithuania.
Ausra RazanskieneNomads UAB, Vilnius, Lithuania.
Yuri GlebaNomad Bioscience GmbH, Biozentrum Halle, Halle (Saale), Germany.
Juozas KupcinskasInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Jurgita SkiecevicieneInstitute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The rapid emergence of multidrug-resistant bacterial species poses a critical threat by reducing the efficacy of antibiotics and complicating infection treatment. Bacteriocins, such as klebicin KvarM, have emerged as promising alternatives to traditional antibiotics due to their targeted antimicrobial activity. In this study, we evaluated the therapeutic potential of Eudragit-coated klebicin KvarM in a mouse model of Methods: Antimicrobial activity of KvarM in comparison to conventional antibiotic therapy with ciprofloxacin was tested in murine models for Results: Our results demonstrated that KvarM was highly effective in reducing Discussion: These findings demonstrate that klebicin KvarM therapy is highly effective for treating intestinal

Indexed as

Anti-Bacterial AgentsBacteriocinsKlebsiella InfectionsKlebsiella pneumoniaeAnimalsBacterial LoadCiprofloxacinDisease Models, AnimalFemaleGastrointestinal MicrobiomeIntestinesMiceRNA, Ribosomal, 16SAnti-Bacterial AgentsBacteriocinsCiprofloxacinRNA, Ribosomal, 16SbacteriocinklebicinKlebsiella pneumoniaemicrobiomemurine models

Identifiers

PMID40182774
PMCPMC11965673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.